NEW YORK (GenomeWeb) – WaferGen Biosystems reported after the close of the market Thursday that its first quarter revenues jumped nearly 700 percent year over year, and the firm cut its loss sharply.

The Fremont, Calif.-based genetic analysis products firm, reported total revenues of $1.4 million for the three months ended March 31, up from $178,487 in revenues for the first quarter of 2013. Its product revenue was $1.3 million versus $95,154 year over year, while license and royalty revenue increased to $125,000 from $83,333.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.